Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Meropol

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Cancer Chemotherapy and Pharmacology|December 29, 2000
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancerD H Ho, W Covington, N Brown, et al.
Cancer|August 10, 2000
Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influencesJ S Mandelblatt, J Hadley, J F Kerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicityN J Meropol, M Porter, L E Blumenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancerC Aggarwal, N J Meropol, C J Punt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinomaM von Mehren, P Arlen, J Gulley, et al.
American Journal of Surgery|September 1, 1996
Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgeryN J Meropol, N J Petrelli, B J Lipman, et al.
British Journal of Cancer|March 11, 2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursA J Zurita, M Khajavi, H-K Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2009
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancerS J Cohen, C J A Punt, N Iannotti, et al.
European Journal of Cancer Care|January 29, 2014
Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriersS Manne, D Kashy, T Albrecht, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Cancer Chemotherapy and Pharmacology|December 29, 2000
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancerD H Ho, W Covington, N Brown, et al.
Cancer|August 10, 2000
Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influencesJ S Mandelblatt, J Hadley, J F Kerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicityN J Meropol, M Porter, L E Blumenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancerC Aggarwal, N J Meropol, C J Punt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinomaM von Mehren, P Arlen, J Gulley, et al.
American Journal of Surgery|September 1, 1996
Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgeryN J Meropol, N J Petrelli, B J Lipman, et al.
British Journal of Cancer|March 11, 2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursA J Zurita, M Khajavi, H-K Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2009
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancerS J Cohen, C J A Punt, N Iannotti, et al.
European Journal of Cancer Care|January 29, 2014
Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriersS Manne, D Kashy, T Albrecht, et al.
Pageof 7